The most quoted and most violated ‘cardinal principle’ of homeopathy is ‘single drug-single dose’. We use multiple drugs in private, and publicly pose as ‘single drug’ prescribers, masking with phrases such as ‘intercurrent’, complementary’, ‘antidote’, ‘anti-miasmatic’, or ‘layer prescriptions’. My point is, even so called ‘single’ drugs are not really ‘single’, but contains diverse types of ‘molecular imprints’.
Some ‘single drug’ prescribers would give a ‘single’ dose of say sulphur cm, and give plenty of biochemic salts or even biochemic combinations, and claim in public that they ‘cured’ the patient with ‘single’ dose of sulphur. Some people would give large doses of mother tinctures along with ‘a single dose of single drug’. Certain others would give a ‘single’ dose of selected similimum, and then frequent doses of ‘complementary’ drugs, for ‘relieving acute complaints’. Prescribing ‘anti-miasmatics’ are also not considered as a violation of ‘single’ drug principles. I am avoiding those who prescribe patented compound drugs from the purview of this discussion, since they are admittedly ‘multiple’ drug prescribers.
A complementary medicine may contain some extra molecular imprints that were not present in original similimum, and that may be helpful in the curative process. Regarding increasing the potency, i cannot agree.
Changing to a new sample from another source, of same drug of same potency, has also gives better response when the curative process come to standstill after a few repetition of a drug
For example, when nux is indicated drug, and given it in 30c with good response. After a few repititions, it becomes standstill. Then you try NUX 30 from another source. It works, same way as you get response from higher potency
Every sample of nux may not contain all types of molecular imprints of constituent molecules of nux vomica. When we change sample, the patient gets those imprints which were absent in first sample.
It is not at all realistic to imagine that the same drug sample of Nux Vomica used for proving is always used for preparing its potencies also. It may have been procured and prepared from another location, climate, environment, time and circumstances. All of these factors may necessarily influence their chemical constitution also. Contaminants and pollutants also differ with time, place and persons who handled it. Yet, we are obliged to call all these different samples as Nux Vomica, and use it as same drug, believing that it is a ‘single drug’!
In reality, potentized Nux Vomica we get now from pharmacies are prepared from samples very much different from the samples used for proving it two hundred years back. It might not necessarily be the same contaminations and foreign molecules which happen to be mixed with the drug during procurement and potentization. Entirely new type of impurities and foreign molecules, different from proven samples, shall definitely get mixed with drugs while potentizing. Naturally, these contaminants and foreign molecules also get subjected to potentization along with original drug molecules. It is evident that the homeopathic potencies of Nux Vomica we get from pharmacies contain the potentized forms of these new contaminant molecules also. In other words, they are mixed with potentized forms of these unknown substances, entirely different from those were subjected to proving. We cannot ignore the fact that we are not using potencies of same drug, that have been proved earlier and recorded in the materia medica, eventhough we call it with same name. It is composed of an entirely different mixture, much more different in molecular structure from the one subjected to original proving. We use the potentized form of this new combination, on the basis of symptoms produced by another combination earlier, using the therapeutic principle ‘Similia Similibus Curentur’. Is not this realization somewhat emberassing? Unless we provide convincing solutions to the ethical, theoretical and practical problems raised by this situation, it would be unfair to continue claiming that we are using ‘single drugs’!
There are a few more points to be considered in association with the issue of ‘single drug’. Chances of drug samples used in proving being contaminated with various environmental particles and foreign molecules should be seriously considered here. Especially in the olden days of most of the drug provings, our knowledge regarding environmental pollutions and contaminations was very limited. During drug proving, molecules of such contaminants also would have obviously undergone proving, along with original drug molecules. Especially for homeopaths, who are convinced about the power of micro doses, this factor cannot be overlooked. The water, alcohol, sugar of milk etc., used in the process of preparing drugs for proving may also have various contaminants. The vessels, utensils, equipment, tools, air, and provers themselvs also may add their own contaminations. These contaminants and impurities also would have been subjected to proving along with original drugs, and their symptoms also included in our materia medica unknowingly, although we don’t take these factors seriously into account. We should be aware of the fact that the biological deviations created in the prover by these un-recognized foreign molecules are also included by us in the accounts of medicinal substances used for proving. It means that at least some of the symptoms we learn in the Materia Medica of a drug may not be actually related to that drug at all, but to the contaminants. This issue will have to be considered in more details later, when discussing about ‘materia medica’.
In homeopathic terminology, any form of drug substance used as a sample for “proving” is considered to be a single entity. It is called a ‘single drug’, even though it may be a complex mixture of several substances. For example, an alcoholic tincture extracted from the Nux Vomica plant is evidently a mixture of many types of enzymes, alkaloids, glycosides, phytochemicals, and other organic and inorganic molecules. Over and above the natural organic contents, various elements and chemical molecules absorbed from the environment will also be part of that tincture. It may also contain various accidental contaminants and pollutants also. In spite of all these possibilities, we consider Nux Vomica tincture is a “single” medicinal substance, and we often talk about a “Nux Vomica personality” as such!
If we introduce a sample of Nux Vomica tincture into the living organism for ‘proving’, its constituent molecules are instantly subjected to various processes such as disintegration, ionization, hydration and certain chemical transformations. Individual constituent molecules are carried and conveyed through blood and other internal transport systems into the cells in different parts of the body. They interact with various enzymes, receptors, metabolites and other biological molecules inside the organism. These interactions are decided and directed by the specific properties such as configuration and charge of active groups of individual drug molecules, and their specific affinity towards biological target molecules. It is very important to note that Nux Vomica interact with different biological molecules, not as a singular entity, but as individual constituent molecules and ions. These individual drug molecules and ions are capable of binding to some or other biological molecules, effecting configurational changes in them, and thereby inhibiting the essential bio-chemical processes which can take place only with their presence and mediation. Such molecular inhibitions in various bio-chemical pathways result in a condition of pathology, expressed as a train of subjective and objective symptoms, due to the involvement of various neuro-mediator and neuro-transmitter systems.
The symptoms we get from the proving of Nux Vomica are in reality the results of diverse deviations in different bio-chemical processes and pathways, created by the constituent drug molecules in their individual capacity and specific configurational affinity. Each type of molecules contained in Nux Vomica binds only to a specific group of biological molecules, and creates their own individual groups of symptoms. Suppose we could completely remove all molecules of a particular alkaloid from a sample of Nux Vomica before it is used for proving. Naturally, during the process of proving, we shall be missing the groups of symptoms that should have been created in the organism by the molecules of that particular alkaloid. This type of proving may be called ‘differential proving’. By conducting such differential provings, we can learn about the particular state of pathology that may be attributed to individual constituent molecules contained in each medicinal substance. More over, this type of scientific differential provings may be utilized to study the biological effects of various constituent molecules of drug materials that we erroneously consider as single drugs. Such differential provings may disprove our mis-conceptions regarding ‘single drug’, at large. This is a subject that warrants serious attention from the part of homeopathic researchers and research institutions.
According to my concept of ‘molecular imprinting’ involved in homeopathic potentization, the active principles of potentized drugs are ‘molecular imprints’ of constituent drug molecules. Since a drug substance constitutes diverse types of independent molecules in it, potentized drugs also would contain different types of ‘molecular imprints’ representing those different drug molecules. These ‘molecular imprints’ acts in their independent capacity of configurational similarity by binding up on pathogenic molecules, producing a therapeutic effect.
As per this view, molecules of drug substances would be completely removed from the medium when the dilution crosses Avogadro limit. That means, even the smallest sized drug molecules will disappear above 23c potency. Hence, I proposed that 30c will be the ideal potency for therapeutic purpose, and further higher potencies will not be different from 30c in medicinal property. SSince drug molecules will be absent above 23c, I presumed that there is no meaning in continuing potentization higher and higher. On that basis, I suggested to use 30c potency only.
But many homeopaths, even those who were not reluctant to accept my ‘molecular imprint’ concept, invited my attention to their experience that when a drug 30c potency acted for some time, a stage reaches where no further improvement is obtained. In such situations, they could create curative response by going to higher and higher potencies of same drug. My friends said that theor experience does not corroborate my suggestion that a drug in all potencies above 30c will be similar in medicinal properties.
I decided to take up this question seriously, and started working up on it. There were many instance where NUX 30 failed but NUX 200 acted. It was also correct that in some cases NUX 30 acted for some time and then came to a standstill, where repeating same potency did not succeed in evoking any response. Then NUX 30 or NUX 1m acted favorably.
There were another experience reported by some homeopaths, and verified by me. When NUX 1m failed, NUX 30 or NUX 200 acted. In my experiments on that lines, I noticed that when a case comes to standstill after a certain period of improvement after using NUX 1m, administration of NUX 30 or NUX 200 was also beneficial, instead of moving to still higher potencies.
Then I started experimenting on another lines. When NUX 30 failed to provide further improvement after a certain stage, I used NUX 30 from another sample obtained from another manufacturer. The result was wonderful. It acted!. I repeated this experiment with different cases, different drugs, different potencies. Finally I came to the conclusion that it was not a question of going higher or lower, but changing of samples, changing of source of potentized drugs. I can now suggest my friends, if you fail with NUX 30, and your are still convinced that the similimum is NUX, use NUX 30 obtained from another manufacturer. It will work. Always keep maximum samples of same drugs in same potencies obtained from different sources, and try all of them before changing your prescription. I have also seen it beneficial to mix all those different samples together and keep as single drug. For example, you can collect NUX 30 from five different manufacturers and mix them together and keep labeled as NUX. And see the difference!
Logical explanation for this phenomenon is very simple. It is associated with the process of molecular imprinting happening in potentization, and the quality of crude drug sample used for potentization. Simply put, each sample of same drug in same potency may differ in their constituent molecular imprints. One sample may miss some ‘molecular imprints’ that may be present in another sample. Each sample provides only partial curative effect, according to the availability of ‘molecular imprints’ present in them. To get a ‘complete’ therapeutic action of a particular drug, we have to use different samples from different sources, one after other, or mixing together.